Zyversa Therapeutics Inc (ZVSA)

May 12, 2025

ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq

May 12, 2025

May 12, 2025

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire

May 12, 2025

May 09, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN

May 09, 2025

May 07, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India

May 07, 2025

May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire

May 07, 2025

May 07, 2025

ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks

May 07, 2025

May 07, 2025

ZyVersa progresses with obesity inflammation treatment - Investing.com

May 07, 2025

May 07, 2025

ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com

May 07, 2025

May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan

May 07, 2025

Apr 30, 2025

ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com

Apr 30, 2025

Apr 29, 2025

ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com

Apr 29, 2025

Apr 29, 2025

How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com

Apr 29, 2025

Apr 29, 2025

Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology

Apr 29, 2025

Apr 29, 2025

ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus

Apr 29, 2025

Apr 29, 2025

Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com

Apr 29, 2025

Apr 29, 2025

ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus

Apr 29, 2025

Apr 29, 2025

ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq

Apr 29, 2025

Apr 29, 2025

ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire

Apr 29, 2025

Apr 29, 2025

Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan

Apr 29, 2025

Apr 24, 2025

ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa

Apr 24, 2025

Apr 24, 2025

ZyVersa progresses with novel inflammation treatment - Investing.com

Apr 24, 2025

Apr 24, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire

Apr 24, 2025

Apr 24, 2025

ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan

Apr 24, 2025

Apr 22, 2025

ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN

Apr 22, 2025

Apr 17, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World

Apr 17, 2025

Apr 10, 2025

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

10 Stocks Fall Behind Amid Market Optimism - Insider Monkey

Apr 10, 2025

Apr 09, 2025

ZyVersa CEO outlines progress in kidney disease drug development - Investing.com

Apr 09, 2025

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 09, 2025

Apr 08, 2025

ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Apr 08, 2025

Apr 08, 2025

ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus

Apr 08, 2025

Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus

Apr 08, 2025

Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus

Apr 08, 2025

Apr 08, 2025

ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks

Apr 08, 2025

Apr 08, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire

Apr 08, 2025

Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm - Investing.com

Apr 07, 2025

Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India

Apr 07, 2025

Apr 04, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 04, 2025

Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia

Apr 02, 2025

Apr 02, 2025

Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World

Apr 02, 2025

Mar 27, 2025

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan

Mar 27, 2025

Mar 27, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World

Mar 27, 2025

Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia

Mar 25, 2025

Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 24, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World

Mar 24, 2025